Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | APP | P05067 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.31 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL113525 | 0.76 | RECQL (0.47) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL14664249 | 0.76 | RECQL (0.47) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL1136763 | 0.76 | RECQL (0.47) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL14095057 | 0.73 | MAPT (0.50) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL13412686 | 0.73 | MAPT (0.50) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL11366201 | 0.71 | RECQL (0.43) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL11296556 | 0.71 | RECQL (0.43) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL10793302 | 0.70 | ALDH1A1 (0.42) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL14300186 | 0.70 | RECQL (0.42) | RECQLMAPTLMNAAPPALDH1A1 | |
| SCHEMBL14095060 | 0.69 | RECQL (0.41) | RECQLMAPTLMNAAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2018-01-04 | — | — | US | disclosed |
| US-9815859-B2 | Tricyclic sulfones as RORγ modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-14 | — | — | US | disclosed |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180002358-A1 | TRICYCLIC SULFONES AS ROR GAMMA MODULATORS | RORC, RORB, RORA | RECQL 4036/4885MAPT 522/4885LMNA 3931/4885 |
| US-20160326195-A1 | TRICYCLIC SULFONES AS RORy MODULATORS | RORB, RORC, RORA | RECQL 4496/4885MAPT 456/4885LMNA 4243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.